General comment minor: Wouldn"t it be more interesting to study trends over age group (Like in Table 3 ) but for specific bacteria as this better would show if the vaccination programs had been effective or not?
General comment minor: There is a lot of text about the dynamic frequency of different serotypes of bacteria. Considering that you have a lot of other tables and figures for this information, and that you obviously consider it important in the manuscript, I think this information belongs in Table form and not in running text Table 2 Minor: The first part of Table 2 is Figure 1 . I think it is redundant to show them twice, and I prefer the Figure ( perhaps with the data as supplementary information?). Table 2 Minor: The different age spans make it difficult to adequately interpret the mean annual incidence. If you only look at that, it looks like it is almost only kids <2 years that are affected by bacterial meningitis, while this is clearly not the case as the mean age for all your patients is a lot higher. I suggest that you try to normalize the groups somehow or insert an adjustment for the number of cases in this Table (if you decide to keep this part of the Table, see previous  comment). unchanged at approximately 10%.
General considerations:
I think the data are useful and the information contributes to our general understanding of the epidemiology of bacterial meningitis in Northern Europe. Considering the aims of the study I do not think that the data are essential in developing or revising treatment guidelines as e.g. empiric antibiotic therapy is hardly going to change unless data on antibiotic susceptibility patterns are also available and reported. Maybe the manuscript could benefit from more focus on the interesting secular trends in incidences of pneumococcal (variations before pneumococcal vaccinations were implemented in 2010) and meningococcal meningitis? Completeness (or lack thereof) of notifications of culture-positive cases of bacterial meningitis to the NIDR should be discussed. There is some redundancy in the text, tables and figures in the results section. Some references may be omitted. Please mention existence or not of a national guideline for antibiotic treatment of bacterial meningitis and adjunctive dexamethasone treatment during the study period? There is also a need for minor language revision.
Minor specific revisions:
1. Please present data as n/N (%) throughout the abstract and manuscript instead of just percentages. Incidence rates should be specified as x.xx/100,000/year. Please be consistent in the order of presenting the data, e.g. incidence rates followed by n/N (%) or vice versa.
2. I do not think that it is appropriate to suggest a linear yearly decline in incidences (e.g.: abstract, results section, lines 4-6) as they clearly vary from year to year for most of the pathogens -as the authors also show in Table 1 and Figure 2. 3. Page 3, third point in "Strengths and limitations". Impact of conjugate vaccine for H. influenzae.: This is not addressed in the study as the vaccine was introduced in 1986 in Finland (ref. 15 ) and the study period begins in 1995 and incidences remain consistently very low throughout. Regarding effect of 10-valent pneumococcal vaccine: Incidences clearly decline in small children as reported in the results section, but overall incidence of pneumococcal meningitis only has a substantial decrease in 2014 (Table 1 and Figure 2) . Interestingly, there is also considerable secular variation in pneumococcal incidences before the introduction pneumococcal vaccine in 2010. Maybe these aspects can be discussed? 9. Page 5, lines 41-43. "Case definitions" states that case fatality is actually categorised as 30-day case fatality rate. This term could be used more consistently throughout the paper as it provides a more accurate measure of mortality. Most patients admitted with bacterial meningitis undergo lumbar puncture within 1-2 days so it seems reasonable to use day of CSF culture as T0?
10. Page 6, lines 6-7. Pathogen specific annual incidence rates. Was a form of standardisation performed (direct or indirect)? If not and data are readily available maybe this could be done to better compare variations in incidence rates?
11. Comparisons of overall median age at the beginning and end of the study period seems rather trivial given the decrease in incidence of meningococcal meningitis and is not very useful clinically, nor in designing clinical guidelines and is too crude a measure for vaccination strategies. The data can be omitted or just mentioned once in the results section.
12. Page 7, lines 22-24. It seems more appropriate to mention ranges of incidence rates of overall meningitis after the reported mean incidence (page 7, line 10).
13. Page 7, line 26. There is a slight discrepancy in case fatality (30-day?) proportion in the study period 2004-2009 (10% vs. 10 .6%)?
14. Page 9, Table 2 . Age category. I would prefer if results were reported first as median and thereafter IQR in the next line. Maybe "means" could be omitted as the variation of age can be ascertained by the IQRs. Table 3 can be omitted (please see comment 2). Statistical analysis used should be reported in the Table header if it is decided to keep it in the manuscript. Table 1 is presented well in Figure 2 . Maybe Table 1 can be omitted or reported in supplementary material? Maybe the yaxis could be labelled as incidence rate/100,000/year. I know it is almost always reported in yearly incidence rates but I prefer it to be specified. Table 2 it seems like figure 1 is redundant (more appropriate as supplementary material)?
I think

The data in
Given the information in
18. Some of the age groups have very low absolute number of deaths (e.g. 4 and 3 deaths among children and adolescents) and it seems a little optimistic to report case fatality percentages with decimals?
19. Please consider displaying incidence rates of pneumococcal and meningococcal meningitis in different age groups during the study period in figures instead, 1 figure for each pathogen with calendar year on the x-axis and incidence rates on the y-axis with different lines representing different age groups (a lot of incidence rates may confuse the reader)? 20. Page 15, line 44 does not really make sense. Maybe it can be rephrased: "Overall incidence rates of listeria meningitis were without significant variations throughout the study period and ranged from 0.04-0.21/100,000/year"? Or something like that. -Could the authors elaborate on the "secular" trends and their proposed impact on meningitis? -The authors offer an explanation attempt for the higher incidence of Listeria monocytogenes meningitis in men than in women, however, it would be nice if they could discuss this finding to a greater extent and maybe offer a hypothesis what the predisposing factors may be in the case of Listeria monocytogenes, as smoking is a logical predisposition for invasive pneumococcal disease, but surely not for meningitis with listeria.
-It might be interesting to see the meningitis rate in young adults (18-25y), as the group 18-49 shows the most cases and young adults would be the "classic" meningococcal meningitis patient and the median age is described to be 18 years.
-The authors describe a serotype switch to non-Hib serotypes causing Haemophilus influenza meningitis. Was there an increase in non-PCV10 serotypes for pneumococcal meningitis?
Minor corrections: -Page 3. Line 26 typo: "underestimated" -Reference 30: Please add a "last accessed on" date
VERSION 1 -AUTHOR RESPONSE
Reviewer: 1 Reviewer Name: Eric Thelin Institution and Country: Karolinska Institutet, Sweden; University of Cambridge, UK Competing Interests: None declared Abstract: Objectives: Major: I lack a hypothesis in the "Objective". Did you believe that there would be different trends of different bacterial origins following vaccinations? This was an evaluation of national surveillance data, thus no formal hypothesis testing was performed. In addition, according to STROBE guideline, listing the hypothesis is not required in the abstract.
Abstract: Conclusions: Minor: "The documentation of changes in causative organisms and age distribution for meningitis cases are important for re-evaluating clinical guidelines for empiric antibiotic therapy" I don"t think this belongs in the Conclusion in the Abstract as you don"t provide any information about antibiotic therapy or guidelines in the Abstract, instead it is well suited for the general conclusion of the manuscript. We revised the conclusions as follows: "Ongoing epidemiological surveillance is needed to identify trends, evaluate serotype distribution, assess vaccine impact and to develop future vaccination strategies." (Page 2, lines 22-23; in the Revision version of the manuscript, after hiding markups) General comment minor: Wouldn"t it be more interesting to study trends over age group (Like in Table form and not in running text. The information on main serotypes was kept in the text body, since it was not feasible to combine data on three different pathogens in one table. Table 2 Minor: The first part of Table 2 is Figure 1 . I think it is redundant to show them twice, and I prefer the Figure ( perhaps with the data as supplementary information?). We removed the information on incidence rates from Table 2 and moved these data to Table 1 . In Table 1 the absolute number of cases is also presented. Figure 1 shows proportions (not incidence rates) of bacterial meningitis cases caused by each pathogen in specific age-groups during the study period 1995-2014. (Table 1 : page 8, Figure 1 : page 10) Table 2 Minor: The different age spans make it difficult to adequately interpret the mean annual incidence. If you only look at that, it looks like it is almost only kids <2 years that are affected by bacterial meningitis, while this is clearly not the case as the mean age for all your patients is a lot higher. I suggest that you try to normalize the groups somehow or insert an adjustment for the number of cases in this Table (if you decide to keep this part of the Table, see previous comment). The data shown are age-group specific incidence rates (thus age span does not affect the ability to compare the data,) calculated as number of cases per person-years at given age span. To add information on the disease burden, we added the number of cases to modified Table 1 . Division to smaller age groups would negatively affect the ability to visually present data and to calculate the trends (because of small numbers or lack of cases in strata). (Table 1, Discussion: The discussion was very well written and really interprets the findings in an adequate way. To be honest, I don"t think your "limitation" to include only culture positive cases is an actually limitation as it decreases the false-positive rate of cases in this study, but I like how you tackle the issue with potential negative CSF cultures in the Discussion. Good job! Thank you.
Ethical consideration: Is it possible to include the ethical reference number (which I believe is a necessity for all medical studies in Finland, including population cohort studies like the current)? Perhaps this study doesn"t need a formal ethical application like the authors suggest. According to the National Institute of Health and Welfare, no ethical review was required for this study. We revised the Ethical consideration section as follows: "Data used in the analysis were collected as a part of national routine surveillance which falls under the existing mandate of THL. No formal Institutional Review Board (IRB) review was required for this study. Personal identifiers were removed after linkage with vital status data". (Page 6, lines 13-15) Summary: While this study perhaps mostly re-inforce already known concepts of meningitis in modern countries, it is well written and provides important information about meningitis epidemiology from a nation-wide approach. It does however give important information suggesting that vaccination programs really helps. I recommend minor revision correcting some minor issues Thank you. General considerations: I think the data are useful and the information contributes to our general understanding of the epidemiology of bacterial meningitis in Northern Europe. Considering the aims of the study I do not think that the data are essential in developing or revising treatment guidelines as e.g. empiric antibiotic therapy is hardly going to change unless data on antibiotic susceptibility patterns are also available and reported. The conclusion of the abstract was revised to (please also see response to reviewer 1): "Ongoing epidemiological surveillance is needed to identify trends, evaluate serotype distribution, assess vaccine impact and to develop future vaccination strategies." (Page 2, lines 22-23)
Maybe the manuscript could benefit from more focus on the interesting secular trends in incidences of pneumococcal (variations before pneumococcal vaccinations were implemented in 2010) and meningococcal meningitis? We added some additional points to the discussion of pneumococcal trends: "Before the introduction of PCV10 considerable variation in pneumococcal meningitis incidence rates was seen. As there was no major changes in surveillance or diagnostic practices in Finland, these changes may be related to emergence of new serotypes, selective pressure from antibiotic use or natural fluctuation in serotypes [24] [25] [26] ." (Page 15, lines 23-25) And meningococcal part: "Changes in rates of meningococcal disease have also been observed in other countries in Europe and worldwide [16] [17] . The reasons for these declines in incidence are not clear but may be related to population immunity to circulating strains, changes in colonizing organisms in the nasopharynx or increasing use of influenza vaccine. Also changes in behavioral risk factors such as lower prevalence of smoking or crowding, might contribute [18] [19] . (Page 15, lines 11-15) We deleted sentence from line 43-44. We propose keeping lines 46-50, since one of our aims was to provide information for developing future prevention strategies.
Completeness (or lack thereof) of notifications of culture-positive cases of bacterial meningitis to the NIDR should be discussed. The completeness of the national surveillance system has not been comprehensively evaluated in Finland, however is assumed to be high (close to 100%) because of electronic reporting of cases directly from the clinical microbiology laboratories to the National Infectious Disease Register.
There is some redundancy in the text, tables and figures in the results section. Some references may be omitted. Please mention existence or not of a national guideline for antibiotic treatment of bacterial meningitis and adjunctive dexamethasone treatment during the study period? In Finland, standard guidelines for antibiotic treatment of septic infections, including bacterial meningitis are available (http://www.kaypahoito.fi/web/kh/suositukset/suositus?id=nak04784&suositusid=hoi50032). We know that adjunctive dexamethasone treatment was previously widely recommended but there are no published clinical data on the prevalence of its use. We added some additional point to the discussion: "Because of lack of clinical data we could not assess the potential impact of treatment changes, such as dexamethasone use, on case fatality." (Page 17, lines 3-4).
There is also a need for minor language revision.
1. Please present data as n/N (%) throughout the abstract and manuscript instead of just percentages. Incidence rates should be specified as x.xx/100,000/year. Please be consistent in the order of presenting the data, e.g. incidence rates followed by n/N (%) or vice versa. We added the information on denominator and numerator as suggested, except when they were provided in the text. The presentation of incidence rates was revised to xx/100,000 person-years.
2. I do not think that it is appropriate to suggest a linear yearly decline in incidences (e.g.: abstract, results section, lines 4-6) as they clearly vary from year to year for most of the pathogens -as the authors also show in We revised the sentence to: "The study documents the sustained population impact of infant conjugate vaccination against Haemophilus influenzae type b; and introduction of 10-valent pneumococcal conjugate vaccination on reducing the burden of bacterial meningitis, as well as decline in meningococcal meningitis due to secular trend. (Page 3, lines 6-9)
Regarding effect of 10-valent pneumococcal vaccine: Incidences clearly decline in small children as reported in the results section, but overall incidence of pneumococcal meningitis only has a substantial decrease in 2014 (Table 1 and Figure 2) . Interestingly, there is also considerable secular variation in pneumococcal incidences before the introduction pneumococcal vaccine in 2010. Maybe these aspects can be discussed? Please see above. The following comment was added. "Before the introduction of PCV10 considerable variation in pneumococcal meningitis incidence rates was seen. As there was no major changes in surveillance or diagnostic practices in Finland, these changes may be related to emergence of new serotypes, selective pressure from antibiotic use or natural fluctuation in serotypes [24] [25] [26] ." (Page 15, 4. Do the authors have access to antibiotic susceptibility results of isolated pathogens? For the purpose of this study, we did not have access to antimicrobial susceptibility data. We added this information to the methods: "Antimicrobial susceptibility data were not available" (Page 5, lines 13-14). Yes, all data were complete for the above mentioned variables. These variables are required and verified for all notifications in the laboratory-based surveillance system in Finland.
Was there an association between year of implementation of dexamethasone in treatment guidelines (if this is recommended in Finland?) and case-fatality proportions?
There is no representative information nor published studies, which would show how widely dexamethasone treatment is used. Also in the routine surveillance data, no clinical information is available. Therefore, assessing the association between dexamethasone and case-fatality proportions is not feasible in this study. We added additional point to the discussion: "Because of lack of clinical data we could not assess the potential impact of treatment changes, such as dexamethasone use, on case fatality. (Page 17, lines 3-4).
9. Page 5, lines 41-43. "Case definitions" states that case fatality is actually categorised as 30-day case fatality rate. This term could be used more consistently throughout the paper as it provides a more accurate measure of mortality. Most patients admitted with bacterial meningitis undergo lumbar puncture within 1-2 days so it seems reasonable to use day of CSF culture as T0?
We changed the text to 30-day case fatality proportion. The 30-day case-fatality proportion was calculated for the date of the first positive culture.
10. Page 6, lines 6-7. Pathogen specific annual incidence rates. Was a form of standardisation performed (direct or indirect)? If not and data are readily available maybe this could be done to better compare variations in incidence rates? Because of considerable variation in rates by age, we showed and analyzed age-stratified incidence rates. Direct standardization would not provide additional information to help interpretation. Additional information on rates in specific age groups and by particular pathogen is now provided in the modified Table 1 . (Table 1, page 8) 11. Comparisons of overall median age at the beginning and end of the study period seems rather trivial given the decrease in incidence of meningococcal meningitis and is not very useful clinically, nor in designing clinical guidelines and is too crude a measure for vaccination strategies. The data can be omitted or just mentioned once in the results section.
Reporting changes in the median age is part of descriptive analysis of data. This provides useful information regarding which age groups are currently most affected by meningitis and indicates that future prevention measures should be targeted to older age groups who experience largest burden of disease.
12. Page 7, lines 22-24. It seems more appropriate to mention ranges of incidence rates of overall meningitis after the reported mean incidence (page 7, line 10). We propose keeping the order of text as in the manuscript, to maintain consistency with other paragraphs and sections. 14. Page 9, Table 2 . Age category. I would prefer if results were reported first as median and thereafter IQR in the next line. Maybe "means" could be omitted as the variation of age can be ascertained by the IQRs. Changed as requested. (Table 2 , page 9)
15. I think Table 3 can be omitted (please see comment 2). Statistical analysis used should be reported in the Table header if it is decided to keep it in the manuscript. We removed table 3 and modified table 1 in such a way that the incidence rates in each 5 year period for each pathogen are stratified by age group and the relative change in rate is presented. Information on statistical analysis method is added as footnote. (Table 1, page 8) 16. The data in Table 1 is presented well in Figure 2 . Maybe Table 1 can be omitted or reported in supplementary material? Maybe the y-axis could be labelled as incidence rate/100,000/year. I know it is almost always reported in yearly incidence rates but I prefer it to be specified. See response 15. We propose keeping revised Table 1 . (Page 8) 17. Given the information in table 2 it seems like figure 1 is redundant (more appropriate as supplementary material)? We removed columns referring to incidence rates in table 2. Figure 1 does not show not incidence rates but proportions (distribution) of cases in different age groups.
We report CFP with one decimal.
19. Please consider displaying incidence rates of pneumococcal and meningococcal meningitis in different age groups during the study period in figures instead, 1 figure for each pathogen with calendar year on the x-axis and incidence rates on the y-axis with different lines representing different age groups (a lot of incidence rates may confuse the reader)? The information on incidence of different pathogens in different age groups is now added to the Table  1. (Page 8) 20. Page 15, line 44 does not really make sense. Maybe it can be rephrased: "Overall incidence rates of listeria meningitis were without significant variations throughout the study period and ranged from 0.04-0.21/100,000/year"? Or something like that.
We rephrased it to: "Overall incidence rates of listeria meningitis did not vary significantly during the study period, ranging from 0.04 to 0. In their well written manuscript the authors present the results of a retrospective study, documenting the incidence development of the most common bacterial meningitis pathogens in Finland during 1995 to 2014. They describe that the mainstay of bacterial meningitis is caused by Streptococcus pneumoniae and Neisseria meningitides. A reduction of meningitis incidence observed by the authors is mainly driven by a reduction of meningitis cases caused by these bacteria. Although an overall reduction of cases could be observed, the case fatality rate remained unchanged from 2004 to 2014. The manuscript raises some minor questions:
-Could the authors elaborate on the "secular" trends and their proposed impact on meningitis?
We added some additional points to the discussion of pneumococcal trends: "Before the introduction of PCV10 considerable variation in pneumococcal meningitis incidence rates was seen. As there was no major changes in surveillance or diagnostic practices in Finland, these changes may be related to emergence of new serotypes, selective pressure from antibiotic use or natural fluctuation in serotypes [24] [25] [26] ." (Page 15, lines 23-25) And meningococcal trends: "Changes in rates of meningococcal disease have also been observed in other countries in Europe and worldwide [16] [17] . The reasons for these declines in incidence are not clear but may be related to population immunity to circulating strains, changes in colonizing organisms in the nasopharynx or increasing use of influenza vaccine. Also changes in behavioral risk factors such as lower prevalence of smoking or crowding, might contribute [18] [19] . (Page 15, lines 11-15) -The authors offer an explanation attempt for the higher incidence of Listeria monocytogenes meningitis in men than in women, however, it would be nice if they could discuss this finding to a greater extent and maybe offer a hypothesis what the predisposing factors may be in the case of Listeria monocytogenes, as smoking is a logical predisposition for invasive pneumococcal disease, but surely not for meningitis with listeria. We added more information on this topic However there is no published studies which would assess the possible reasons for that disproportion in Finland. "L. monocytogenes meningitis cases were 2.5 times more likely to be men. Higher rates of listeriosis in males have also been observed in other studies [7] . However, the reasons are unknown, but may be related to higher prevalence of underlying conditions, alcoholism among men and liver diseases (including alcoholic cirrhosis) [30] ." (Page 16, lines 10-13) -It might be interesting to see the meningitis rate in young adults (18-25y), as the group 18-49 shows the most cases and young adults would be the "classic" meningococcal meningitis patient and the median age is described to be 18 years. We agree with purpose. However, dividing to such small age group would make it difficult to assess the trends because of small numbers. Also, we would prefer consistency in age groups throughout the manuscript.
-The authors describe a serotype switch to non-Hib serotypes causing Haemophilus influenza meningitis. Was there an increase in non-PCV10 serotypes for pneumococcal meningitis? Because of the limited scope of this manuscript we did not assess vaccine impact. This would required more advanced analysis. Study addressing this topic will be probably publish soon by other Finnish study group.
Minor corrections: -Page 3. Line 26 typo: "underestimated" Corrected.
-Reference 30: Please add a "last accessed on" date Added according to suggestions.
